The size of the Global Chlamydia Infection Diagnostics and Therapeutics Market was around USD 2.4 billion in 2020. It is expected to grow at a CAGR of 6.06% to reach USD 3.2 billion by 2025.
Chlamydia is a sexually transmitted disease. The symptoms do not occur early on. It is usually prevalent in areas with poor sanitation. It is the most common STD worldwide. The number of victims has been increasing over the last decade.
An increasing number of cases of these diseases better and complete reporting in emerging economies, augmenting screening coverage, improved funding for better R&D in this area, growing awareness regarding STDs in the developing countries along with the increased healthcare expenditures are the factors driving the growth of this market. Also, accessibility to and availability of hypersensitive diagnostic tests are also boosting the growth of this market. Furthermore, improved insurance coverage in the emerging economies augurs well for this market.
However, the stigma associated with sexually transmitted diseases is the primary restraint of market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Product, End User, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
This research report on the global chlamydia infection diagnostics and therapeutics market has been segmented and sub-segmented on the basis of product, end-user, and region.
Chlamydia Infection Diagnostics and Therapeutics Market – By Product
On the basis of product, the NAAT segment is accounted for the largest market share in 2016 and is predicted to grow robustly in the forecast period. It is closely tailed by DFT in terms of CAGR. This is because NAATs are more sensitive and diagnose better. Macrolides is expected to undergo high growth in the forecast period. It also captures the largest market share and is expected to stay at the top in the forecast period.
Chlamydia Infection Diagnostics and Therapeutics Market – By End User
Chlamydia Infection Diagnostics and Therapeutics Market – By Region
North America is the largest regional market while the Asia Pacific is expected to be the fastest-growing market worldwide.
NOTABLE COMPANIES IN THE MARKET
A list of key market participants leading the Global Chlamydia Infection Diagnostics and Therapeutics Market profiled in this report are Bio-Rad Laboratories, Novartis AG, F Hoffmann-La Roche, Abbott Laboratories, Danaher. Other players in the market include bioMerieux, DiaSorin SpA, Siemens AG, Thermo Fisher Scientific, and Becton Dickinson and Company.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.1 Introduction
5.1.2 Diagnostics
5.1.2.1 Nucleic Acid Amplification Tests (NAATs)
5.1.2.2 Direct Fluorescent Tests
5.1.2.3 PCR
5.1.3 Therapeutics
5.1.3.1 Macrolides
5.1.3.2 Quinolones
5.1.3.3 Sulfonamides
5.1.3.4 Tetracycline
5.1.3.5 Aminopenicillins
5.1.4 Y-o-Y Growth Analysis, By Product Type
5.1.5 Market Attractiveness Analysis, By Product Type
5.1.6 Market Share Analysis, By Product Type
5.2 End User
5.2.1 Introduction
5.2.2 Diagnostics
5.2.2.1 Hospitals
5.2.2.2 Specialty Clinics
5.2.2.3 Diagnostic Centers
5.2.3 Therapeutics
5.2.3.1 Hospital Pharmacies
5.2.3.2 Drugstores
5.2.3.3 Retail Pharmacies
5.2.3.4 Online Pharmacies
5.2.4 Y-o-Y Growth Analysis, By End User
5.2.5 Market Attractiveness Analysis, By End User
5.2.6 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product Type
6.1.3.3 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product Type
6.1.4.3 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product Type
6.1.5.3 By End User
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Bio Rad laboratories
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis AG
8.3 F Hoffmann-La Roche
8.4 Abbott Laboratories
8.5 Danaher
8.6 bioMerieux
8.7 DiaSorin SpA
8.8 Siemens AG
8.9 Thermo Fisher Scientific
8.10 Becton Dickinson and Company
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
